Home › US companies › Penumbra

Penumbra

PEN · NYSE · Surgical & Medical Instruments & Apparatus
Insider buys (12 months)
0
Insider sales (12 months)
$11.1M
8-K reports (12 months)
8
Tracked investors holding
2

At a glance

Penumbra reported 2025 revenue of $1.4B, up 17.5% from $1.19B in 2024. Over 4 years since 2021 ($747.6M), that is growth of about 17.1% a year. Operating margin was 13.5%, up from -1% in 2021. 2025 was the highest revenue year in this period. The company posted a loss in 2021.

In the last 12 months 5 insiders reported 0 open-market purchases and 13 sales ($11.1M). All of the sales were made under pre-arranged 10b5-1 trading plans. The largest was a sale of $4.6M by Director Arani Bose on Dec 15, 2025.

Penumbra filed 8 current reports (Form 8-K) in the last 12 months, most often for results of operations (6), shareholder vote results (2) and material agreement (1). It reported a material agreement or a completed acquisition or disposal 1 time.

2 of the 20 investors tracked here held Penumbra at the last quarter end, worth $25.6M combined. It is the largest weight for Renaissance Technologies (0% of its portfolio), followed by Bridgewater Associates (0%). Added: Renaissance Technologies. Reduced: Bridgewater Associates.

Annual results

2021
Revenue $747.6M
Op. -$7.5M
2022
Revenue $847.1M
Op. $6.1M
2023
Revenue $1.06B
Op. $73.6M
2024
Revenue $1.19B
Op. $9.3M
2025
Revenue $1.4B
Op. $189.2M
RevenueOperating income (or net income)SEC XBRL annual filings, fiscal years mapped to calendar years
Year20212022202320242025
Net income$5.3M-$2M$91M$14M$177.7M
Diluted EPS$0.14$-0.05$2.32$0.36$4.52

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Renaissance TechnologiesAdded$25.1M · 0.0% · held 5 quarters
Bridgewater AssociatesReduced$499K · 0.0% · held 8 quarters

Weight is the share of each investor's portfolio, as of the quarter end.

Current reports (8-K, last 12 months)

Insider open-market trades (last 12 months)

Source: SEC EDGAR. How figures are combined